Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Evome Medical Technologies Inc V.EVMT

Alternate Symbol(s):  LNDZF

Evome Medical Technologies Inc. is an international medical device company, which is focused on human performance and rehabilitative solutions. The Company’s products include Biodex Rehab product, Damar Plastics product, Mio-Guard product, Simbex services, and SDP product. Its Biodex Rehab products include Isokinetic Systems, Gait Trainer, Body-Weight Supported Training, Cycles and Ergometers, and Squat-Assist Trainer. Its Mio-Guard products include bags, cases and kits, braces, and supports, diagnostics and instruments, furniture, and equipment, padding and splinting, personal protection, sanitizers and disinfectants, and tapes and wraps. Its applications include fall risk screening and conditioning, patient-driven payment model (PDPM), wellness, sports medicine solutions, neurological involvement, safe patient handling and mobility, and senior living and rehabilitation. It offers concussion, fall screening and balance assessment and training programs.


TSXV:EVMT - Post by User

Post by AD31313on Jul 31, 2017 9:21am
251 Views
Post# 26527932

LND to pursue strategic review!!!!! Company received a bid!

LND to pursue strategic review!!!!! Company received a bid!

Inspira Financial Inc. Announces Its Board Has Decided to Explore Strategic Alternatives

V.LND 

 

BOCA RATON, Fla., July 31, 2017 (GLOBE NEWSWIRE) -- 

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN. 

Inspira Financial Inc. (TSX VENTURE:LND) ("Inspira" or the "Company"), a company currently focused on providing revolving lines of credit, as well as billing and collection services, to the highly fragmented U.S. mental health and addiction services market, announced it has initiated its strategic review of its businesses within the context of the capital markets.

The Company also announced the release of its unaudited financial statements for the three-month period ended May 31, 2017 and accompanying Management's Discussion & Analysis (MD&A), which are available at www.sedar.com

“In speaking with many Canadian shareholders and Canadian capital market participants over the past few months, it has become clear that Inspira has significant capital market perception issues that may be hard to overcome quickly,” said Edward Brann, Director of Inspira. “I bought a significant stake in this company earlier in the year with an eye toward building a world-class mental health billing and lending company. While I believe the market for such a product is strong and growing, and Inspira certainly has the cash to develop the product, the Board is considering whether a public company structure is capable of reflecting the true value of Inspira’s current business. Having recently received written indication of interest from an arm’s length party with respect to an acquisition of the Company’s business, the Board has decided to pursue various strategic alternatives to enhance shareholder value, including the sale of some or all of the assets of Inspira, a merger or other business combination, the outright sale of Inspira, a spin out, or some combination thereof. Prospective purchasers have shown interest in purchasing the billing and collection division for cash on the basis that taking on the opportunity in a private setting would permit them the necessary time to give this business a chance at greater growth and success without the quarterly pressures of being a public company. I would expect that any such transaction would be completed only if shareholders were provided with an ability to share in the growth of the sold business. Additionally, I want to be clear that unless we receive a compelling offer, our strategy is to look to monetize our cash and loan book separately from the billing and collection business.”

Until a final transaction, if any, is known, the Company is suspending its quarterly dividend payments.

There can be no assurance that this process or the current discussions with potential acquirers will result in any specific transaction. Accordingly, the Company does not intend to make further disclosure unless and until its Board approves a specific action or otherwise concludes the review of strategic alternatives. It is expected that any such transaction would be subject to regulatory and shareholder approval.

Summary of Key Financial and Market Information as of May 31, 2017:

  • Total cash and cash equivalents as of May 31, 2017 were $9,280,584
  • Total credit receivables as of May 31, 2017 were $10,107,375
  • The Company currently has reduced its monthly burn per month as it builds its billing, collections and lending business.

As part of the strategic review, Mr. Edward Brann will assume the role of interim Chief Executive Officer again effective today.



Bullboard Posts